A method, system, and computer program product for producing an organism specific diagnosis of septicemia in infants is disclosed. The method involves measuring the levels of one or more biomarkers against predefined threshold values and interpreting these levels to arrive at the diagnosis. Other techniques may introduce a preliminary step of identifying higher risk subjects, as well as the integration of such methods into the final diagnostic methodology. One aspect of a technique of this method may involve measuring one more cytokines to detect specific classes of infective organisms, such as Gram-negative bacteria.

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

A method for manufacturing a measuring kit is disclosed. The method for manufacturing a measuring kit includes steps of providing a carrier including a substrate having a surface; coating a silane onto the surface of the substrate; providing an organic molecule; adding the organic molecule onto the carrier; outputting a microwave energy by a coaxial cable; and emitting the microwave energy through a radiator to microwave the carrier and the organic molecule uniformly to coat the organic molecule onto the carrier carrying the silane, wherein the measuring kit is used to apply an enzyme-linked immunosorbent assay.

Diagnostic screening tests that can be used to identify if a patient is a good candidates for an implantable vagus nerve stimulation device. One or more analyte, such as a cytokine or inflammatory molecule, can be measured from a blood sample taken prior to implantation of a vagus nerve stimulator to determine the patient's responsiveness to VNS for treatment of an inflammatory disorder.

A kit for determining whether a patient will develop severe dengue includes a binding partner for olfactomedin 4 and a binding partner for at least one member selected from the group consisting of dengue virus NS1 protein, platelet factor 4, and 2-macroglobulin. The kit may further include a label reagent capable of generating a detectable signal.

The present application relates to a erythrocyte-derived magnetic immune particle and uses thereof, according to an aspect, the erythrocyte-derived magnetic immune particle include an erythrocyte-derived cell membrane, which may minimize in vivo side effect, and may be used to detect and remove various type of substances (for example, a pathogenic substance, an inflammatory cytokine, blood glucose, a cancer-related substance, and a brain disease-related substance, etc.) from a sample with excellent efficiency, which may be useful for diagnosing, preventing, or treating various type of diseases, including an infectious disease, an inflammatory disease, diabetes, cancer, and brain disease.

A method for determining, in vitro, the probability of a patient developing severe dengue, based on a blood sample, according to a) the quantity in the blood sample of at least one marker, which is olfactomedin 4, is determined, b) the quantity of olfactomedin 4 determined in step a) is compared with a reference quantity of the marker obtained from a group of individuals who have been diagnosed with non-severe dengue, wherein, if the quantity of olfactomedin 4 determined in step a) is greater than the reference quantity established in step b), it is determined that the patient will develop severe dengue.

A method is described to obtain a class of embryos having a higher implantation potential than from morphology selection alone by selecting from a plurality of embryos, obtained by fertilizing the plurality of oocytes, a class of embryos having a high implantation potential. The selection is determined from a level of granulocyte-colony stimulating factor (G-CSF) present in the follicular fluid (FF) of each oocyte in the plurality of oocytes.

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.